 | Up a level |
2023
Tzaridis, Theophilos 
ORCID: 0000-0001-9651-1144, Weller, Johannes, Bachurski, Daniel ORCID: 0000-0001-9168-9680, Shakeri, Farhad ORCID: 0000-0003-1161-1942, Schaub, Christina, Hau, Peter, Buness, Andreas, Schlegel, Uwe, Steinbach, Joachim-Peter, Seidel, Clemens, Goldbrunner, Roland, Schaefer, Niklas, Wechsler-Reya, Robert J., Hallek, Michael ORCID: 0000-0002-7425-4455, Scheffler, Bjoern, Glas, Martin, Haeberle, Lothar, Herrlinger, Ulrich, Coch, Christoph, Reiners, Katrin S. and Hartmann, Gunther
(2023).
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression.
Int. J. Cancer, 152 (2).
S. 308 - 320.
HOBOKEN:
WILEY.
ISSN 1097-0215
2022
Weller, Johannes ORCID: 0000-0001-5818-5392, Schaefer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael ORCID: 0009-0000-1485-7820, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Guresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich and Schneider, Matthias
(2022).
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
J. Neuro-Oncol., 159 (1).
S. 95 - 102.
NEW YORK:
SPRINGER.
ISSN 1573-7373
Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael ORCID: 0009-0000-1485-7820, Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Gueresir, Erdem, Schmid, Matthias ORCID: 0000-0002-0788-0317, Schuss, Patrick ORCID: 0000-0002-5806-2576, Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank ORCID: 0000-0003-4892-6104, Herrlinger, Ulrich and Schneider, Matthias
(2022).
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Trials, 23 (1).
LONDON:
BMC.
ISSN 1745-6215
2021
Werner, Jan-Michael ORCID: 0000-0001-7147-4594, Weller, Johannes, Ceccon, Garry, Schaub, Christina, Tscherpel, Caroline, Lohmann, Philipp ORCID: 0000-0002-5360-046X, Bauer, Elena K., Schaefer, Niklas, Stoffels, Gabriele, Baues, Christian, Celik, Eren, Marnitz, Simone, Kabbasch, Christoph, Gielen, Gerrit H., Fink, Gereon R. ORCID: 0000-0002-8230-1856, Langen, Karl-Josef, Herrlinger, Ulrich and Galldiks, Norbert
(2021).
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Clin. Cancer Res., 27 (13).
S. 3704 - 3714.
PHILADELPHIA:
AMER ASSOC CANCER RESEARCH.
ISSN 1557-3265
2020
Tzaridis, Theophilos, Reiners, Katrin S., Weller, Johannes, Bachurski, Daniel ORCID: 0000-0001-9168-9680, Schaefer, Niklas, Schaub, Christina, Hallek, Michael, Scheffler, Bjoern, Glas, Martin, Herrlinger, Ulrich, Wild, Stefan, Coch, Christoph and Hartmann, Gunther
(2020).
Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature.
Int. J. Mol. Sci., 21 (19).
BASEL:
MDPI.
ISSN 1422-0067
Tzaridis, Theophilos, Weller, Johannes, Bachurski, Daniel ORCID: 0000-0001-9168-9680, Schaefer, Niklas, Schaub, Christina, Hallek, Michael, Scheffler, Bjoern, Glas, Martin, Hartmann, Gunther, Herrlinger, Ulrich, Wild, Stefan, Coch, Christoph and Reiners, Katrin
(2020).
ANALYSIS OF SERUM MIRNA IN GLIOBLASTOMA PATIENTS: TARGETED ENRICHMENT OF EXTRACELLULAR VESICLES ENHANCES SPECIFICITY FOR PROGNOSTIC SIGNATURE.
Neuro-Oncology, 22.
S. 10 - 11.
CARY:
OXFORD UNIV PRESS INC.
ISSN 1523-5866
Werner, Jan-Michael, Ceccon, Garry, Weller, Johannes, Schaub, Christina, Tscherpel, Caroline, Lohmann, Philipp, Bauer, Elena, Schaefer, Niklas, Stoffels, Gabriele, Kabbasch, Christoph, Baues, Christian, Marnitz, Simone, Fink, Gereon R., Langen, Karl-Josef, Herrlinger, Ulrich and Galldiks, Norbert (2020). DIAGNOSIS OF PSEUDOPROGRESSION FOLLOWING RADIOTHERAPY PLUS LOMUSTINE-TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS USING FET PET. Neuro-Oncology, 22. S. 152 - 155. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866
2019
Herrlinger, Ulrich, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter ORCID: 0000-0003-3894-5053, Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schaefer, Niklas, Kebir, Sied, Weller, Johannes ORCID: 0000-0001-5818-5392, Schaub, Christina, Stummer, Walter, Tonn, Joerg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang ORCID: 0000-0002-6171-634X, Weller, Michael, Fimmers, Rolf, Schmid, Matthias ORCID: 0000-0002-0788-0317, Hattingen, Elke ORCID: 0000-0002-8392-9004, Pietsch, Torsten, Coch, Christoph and Glas, Martin
(2019).
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Lancet, 393 (10172).
S. 678 - 689.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X
Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke ORCID: 0000-0002-8392-9004, Schaefer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Weller, Johannes ORCID: 0000-0001-5818-5392, Mack, Frederic, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Baehr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Haenel, Mathias, Sabel, Michael, Gerlach, Ruediger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin and Herrlinger, Ulrich
(2019).
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
J. Neuro-Oncol., 144 (3).
S. 501 - 510.
NEW YORK:
SPRINGER.
ISSN 1573-7373
Weller, Johannes ORCID: 0000-0001-5818-5392, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich and Schaefer, Niklas
(2019).
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol., 20 (10).
S. 1444 - 1454.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-5488
2018
Weller, Johannes, Tzaridis, Theophilos, Steinbach, Joachim, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Schaub, Christina, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Matthias, Schmid, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich and Schaefer, Niklas
(2018).
QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA.
Neuro-Oncology, 20.
S. 218 - 220.
CARY:
OXFORD UNIV PRESS INC.
ISSN 1523-5866
2017
Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim, Schlegel, Uwe, Sabel, Michael, Hau, Peter, Kortman, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Baehr, Oliver, Uhl, Martin, Tabatabai, Ghazaleh, Ringel, Florian, Schmidt-Graf, Friederike, Brehmer, Stefanie, Weyerbrock, Astrid, Bullinger, Lars, Vajkoczy, Peter, Vatter, Hartmut, Schaefer, Niklas, Kebir, Sied, Weller, Johannes, Stummer, Walter, Simon, Matthias, Keil, Vera ORCID: 0000-0001-8699-3506, Nelles, Michael, Fimmers, Rolf, Pietsch, Torsten, Hattingen, Elke, Coch, Christoph and Glas, Martin
(2017).
PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial.
Neuro-Oncology, 19.
S. 13 - 15.
CARY:
OXFORD UNIV PRESS INC.
ISSN 1523-5866